Spruce Biosciences, a biotechnology company developing novel therapies for rare endocrine disorders, is currently conducting a Phase 2 study to evaluate the safety and effectiveness of a new potential treatment in adults with classic CAH.

The investigational treatment, called SPR001, is a non-steroid, daily oral medication. SPR001 works through a different mechanism of action than the traditional steroids that are often used to treat CAH. SPR001 works at the level of the pituitary gland to reduce the abnormally high levels of adrenocorticotropic hormone (ACTH) and androgens seen in patients with CAH. By lowering hormones such as ACTH and androgens, SPR001 is designed to improve CAH symptoms and allow patients to reduce their daily intake of steroids.

Patients who qualify for the Phase 2 study will receive all study-related care and medication at no cost, and will be compensated for time and travel.

If the results of this initial Phase 2 study are promising, future clinical studies will be conducted with the eventual goal of providing patients and doctors with the first FDA-approved treatment specifically for CAH.

To qualify for the study, patients must be 18 years of age or older, have a diagnosis of classic CAH, and be currently taking a steroid for CAH (e.g., hydrocortisone, prednisone, dexamethasone, etc.). To learn more about this clinical trial or to complete a prescreen questionnaire to see if you are eligible, please visit www.CAHClinicalTrial.com or https://clinicaltrials.gov/ and refer to study number: NCT03257462.

December 1, 2017

Dear CARES Foundation Patient and Family Community,

Spruce Biosciences, a San Francisco-based biotechnology company developing novel therapies for rare endocrine disorders, is currently conducting a Phase 2 study to evaluate the safety and effectiveness of a new investigational treatment (SPR001) in adults with classic CAH. Six clinical study sites across the U.S. have been activated and are currently screening patients for this study.

The investigational treatment, SPR001, is a non-steroid, daily oral medication that is intended to lower excess androgen levels, improve the symptoms of CAH and allow patients to reduce their daily dose of steroids. Patients who quality for the study will receive all study-related care and medication at no cost, and will also be compensated for time and travel. We are working with CARES to provide updates on this study via their website and social media.

To learn more about this clinical trial or to complete a prescreen questionnaire to see if you are eligible, please visit www.CAHClinicalTrial.com or https://clinicaltrials.gov/ and refer to study number NCT03257462.

Should you have any questions regarding this announcement, please feel free to contact us at [insert your appropriate contact info here].

Thanks in advance for your attention and consideration as we continue to work diligently to bring a new therapy to the CAH community.

Sincerely,

[insert name, title, etc.]